The Company manufactures interventional cardiology coronary stents. The Company’s HQ is in Western India and its manufacturing facility is in northern India. The Company began operations in 2011, and over the past two years has developed a scalable business model with successful commercial operations.
Business:
Manufacturing, marketing and distribution of coronary stents in domestic and export markets.
Product
- Proprietary stent design; one of the lowest strut thickness of 59 microns, high radial strength and flexibility.
- Four products with 45+ SKUs; Indian FDA approved and CE marked.
- Registrations completed in 6 countries and under process in 45+ countries (including Europe).
Distribution network
- Strong relationships with reputed hospitals with high volumes and good payment track record.
- Efficient network in 5 countries and 8 Indian states (regions with high demand).
- Rapidly growing network both in India and international market.
Revenue
- FY14 – INR 194 mn revenue expected based on existing monthly revenues and orders in hand.
- Poised for exceptionally high revenue growth due to high acceptability of the product & growing network.
- FY18 – INR 1,772 mn revenue projected.
Margins
- EBIDTA margins expected for FY14 ~30% EBIDTA.
- Margins to improve going forward with growth in revenue and economies of scale.
- FY18 – 48% margins projected.
Shareholding
100% with promoter family & friends
Opportunity
Acquisition of majority control in the Company